Growth rate (cm/yr) Estrogen at age 12 Estrogen at age 15

Slides:

Advertisements

Similar presentations

Treatment of Precocious puberty

Advertisements

Short Stature in Noonan Syndrome: Demography and Response to Growth Hormone Treatment in KIGS Barto J Otten KIGS 10 Year Book, 1999.

Development of the KIGS Model for Predicting Growth Response to Growth Hormone Replacement Therapy in Children with Idiopathic Growth Hormone Deficiency.

Growth Hormone Treatment in Children with Intrauterine Growth Retardation and Silver-Russell Syndrome Pierre Chatelain KIGS 10 Year Book, 1999.

Final Height Following Growth Hormone Treatment of Idiopathic Growth Hormone Deficiency in KIGS Wayne S Cutfield, Anders Lindberg, Pierre Chatelain, David.

This is a sentence made using 10 point font. This is a sentence made using 12 point font. This is a sentence made using 14 point font. This is a sentence.

Growth Hormone Treatment of Children with Prader-Willi Syndrome as Reported to KIGS: First-Year Growth Hormone E Martin Ritzén KIGS 10 Year Book, 1999.

Patient #1 Patient #2 Patient #3 Normal Lung

Adverse Events - Demographics

0.24→0.37 mg/kg/week (▲) and 0.37 mg/kg/week ().

ERT, estrogen replacement therapy

Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.

number / total number (percent)

with Special Reference to GH

Figure 1. Serum B-ALP levels in normal male (•) and female (○) children as a function of age. Serum B-ALP levels were increased during infancy and puberty.

Cytokine-induced rapid ICAM-1 expression on human ASM promotes adhesion of activated T lymphocytes. Cytokine-induced rapid ICAM-1 expression on human ASM.

Chapter 9 Age and Sex-Related Differences & Their Implications for Resistance Exercise.

Pretreatment of VSV-GPΔ to form VSV-GP19K rescues infection in the α5β1-integrin-negative CHO cells. Pretreatment of VSV-GPΔ to form VSV-GP19K rescues.

Endothelial Dysfunction in Patients With Lone AF and AF Patients With Comorbidities Compared With That in Controls Comparisons are shown among control.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

GH peak (µg/l) Regression analysis of the GHRH+GHRP-6-elicited GH peaks plotted against body mass index (BMI), in 366 subjects with no endocrine pathology.

Difference plots for each oxidation type and duration, showing the mean spectrum minus the mean untreated spectrum. Difference plots for each oxidation.

Major physical anomalies according to parental origin of retained Xp

#significant difference versus baseline (P<.05).

Effects of 5 yr of GH substitution in 118 GH-deficient adults on serum concentrations of TC, HDL-C, LDL-C and TG as well as on blood glucose, serum insulin.

Bones mass (BMC) and standing height in patients with COGHD compared with normal Russian adults. All values are compared with results obtained.

Relationship between karyotype and basal characteristics at GH start

Fig.1. The dose of GH administered to patients in different age groups after 1 year of GH replacement therapy. Data are shown as mean, median and 10th-90th.

A B GH and IGF-1 action on the effect of oral estrogen Pituitary Gland

Controls r=-0.82; P< GHD r=-0.84; P< Mean IMT (mm)

Control Subjects MPHD Patients Control Subjects MPHD Patients

Increased dormancy of LKS CD150+ cells associated with steady-state aging. Increased dormancy of LKS CD150+ cells associated with steady-state aging. (A)

No GH (n=19) Treated with GH (n=67) Mean (SD) Range Mean (SD) Range

Box plots of quality scores over positions in sequenced reads.

GH dose 12 months of treatment 24 months of treatment Low Medium High

Fig.1 Simple least-squares regression of the relationship between the log of peak GH concentration on standard GH stimulation tests and serum IGF-1 concentrations.

 Height SDS  Weight SDS

Phenotypes in shox haploinsufficiency

 Gruppe A: 0,033mg WH/kg x die  Gruppe B: 0,067mg WH/kg x die

Height velocity (cm/yr) Height velocity (cm/yr)

STAI: higher scores reflect more anxiety (scores 20-80).

Sensivity Sensivity Sensivity 100-specify 100-specify 100-specify

Baseline Clinical Characteristics

Comparison between groups

CI, confidence interval (95%)

Fig. 6. CXM correlates with age and growth velocity.

Abbildung mod. nach Van Pareren, 2004

Change in LBM (%)‏ LD CD LD CD LD CD

Box plots showing the relative difference in distribution of mtDNA copy number per cell between patients with ESRD and healthy control subjects frequency.

The effects of KY19382 on growth plate senescence and longitudinal bone growth. The effects of KY19382 on growth plate senescence and longitudinal bone.

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

Distribution plot of the differentially expressed genes.

Figure Meta-analysis of 9 studies of patients with attention-deficit/hyperactivity disorder (ADHD) vs controls Meta-analysis of 9 studies of patients with.

Increase in adults treated at children's hospitals, 1999–2012, according to age group. Increase in adults treated at children's hospitals, 1999–2012, according.

Lifestyle intervention was associated with improved cardiorespiratory fitness. Lifestyle intervention was associated with improved cardiorespiratory fitness.

Variation analysis for differences between transcription levels on the duplicated alleles. Variation analysis for differences between transcription levels.

Effect of RO and placebo on IOP

Frequency plots of copy number aberrations (CNAs) are shown for (A) baseline endobronchial lesions of cases (n=12) and (B) baseline endobronchial lesions.

Mean decline in grip strength with aging is shown for participants categorized by baseline quartile of 2 h glucose (2HG). Mean decline in grip strength.

Spider plot of the unstandardised SF-36v2 subscales, comparing our HCM population with the mean for the general population (aged 45–54 years). Spider plot.

Analysis of potential contribution of spike timing to plasticity.

Change in total kidney volume and renal function over 3 years of tolvaptan compared with matched control and their correlation for individual subjects.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle distribution. The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle.

Tamoxifen-treated patients.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

SY-1425 induces maturation in RARA-high AML

Relative abundance of taxa in the 16S rRNA PCR amplicon and gDNA mock communities. Relative abundance of taxa in the 16S rRNA PCR amplicon and gDNA mock.

A, Raw growth data were plotted by gender and adiposity classification group at age 2 months (gray box), and mean BMI for each group is shown over time.

Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis (HD) patients. Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis.

Presentation transcript:

Growth rate (cm/yr) Estrogen at age 12 Estrogen at age 15 Expected untreated (Lyon, et al.) Chronological Age (yr) Annual growth velocity for patients receiving GH and beginning estrogen at either 12 or 15 yr of age. The mean growth velocity ± 1 SD ist shown (n=11-26 in 12-yr-old group; n=16-29 in 15-yr-old group). Data for untreated patients are from Ref.2. Abbildung mod. nach Chernausek, 2000

Change in Bone Age (yr) Chronological Age (yr) Effect of estrogen on bone age advancement. Patients beginning estrogen at age 12 yr are compared with those that received estrogen after the age of 15 yr. The mean change in bone age occurring each year is plotted ±1 SD. The number of patients analyzed for each grouping is illustrated. The rate of bone maturation was statistically significantly different between the groups (P=0.004) Abbildung mod. nach Chernausek, 2000

Height gain for patients treated with GH compared to controls Height gain for patients treated with GH compared to controls. Data are plotted for individual patients with the most recent height minus the pretreatment projected height determined as indicated in the text. The mean values for each group are indicated by a dash. Control patients were matched from a historical database as described in the text Most Recent Minus Projected Height (cm) Control (14) Estrogen at age 12 (26) Estrogen at age 15 (29) Control (55) Estrogen after 1 yr (51) Baseline Age < 11 yr Baseline Age > 11 yr Abbildung mod. nach Chernausek, 2000